ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
2,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2,3,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
2,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2,7,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2,8,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
2,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2,10,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2,11,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
5,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5,3,Urinary hesitation,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
6,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
6,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
6,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
7,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
7,3,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
7,4,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
7,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
7,6,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
7,7,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
8,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
8,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
9,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
9,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
10,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
10,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
10,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
11,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
11,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
12,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
13,1,Infusion site macule,Infusion site reactions,Administration site reactions,Genrl,N
13,2,Infusion site swelling,Infusion site reactions,Administration site reactions,Genrl,N
14,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
14,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
15,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,Y
16,1,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
17,1,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
17,2,Viral upper respiratory tract infection,Viral infections NEC,Viral infectious disorders,Infec,N
18,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
18,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
19,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
19,2,Intravascular haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
20,1,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
20,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
20,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
20,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
21,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
21,2,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
21,3,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
21,4,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
21,5,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
21,6,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
21,7,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
21,8,Breakthrough haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
21,9,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
21,10,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
21,11,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
21,12,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
